The Absorption, Metabolism and Excretion of [14C]SH-1028 in Chinese Healthy Male Volunteers

Inclusion Criteria: 1. Healthy male volunteers between the age of 18 to 50 years old； 2. Body weight \>=50 kg, Body mass index between 19 and 26 kg/m2 (including 19 and 26 kg/m2); 3. Normal physical findings, clinical laboratory values, vital signs and 12-lead ECG, or any abnormality that is non-clinically significant; 4. Male subjects of reproductive potential with partners will be instructed to, and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 6 months after discontinuing treatment with the investigational product.; 5. Signing the informed consent forms by oneself; 6. Be able to communicate well with the researcher and be able to complete the trial in accordance with the program. Exclusion Criteria: 1. History of or current clinically significant cardio, pulmonary, endocrine, metabolism, renal, hepatic, gastrointestinal, dermatology, infection, hematology, neurological, mental disease or disorder; 2. Positive test for HBs-Ag, HCV-Ab, HIV-Ab, or syphilis antibody; 3. Long-QT syndrome or family history of it, or QTcF interval \> 450 mses; 4. Allergies, have allergies to drugs or foods; or have known allergies to the components of the drug; 5. Those who smoked daily \>5 sticks of cigarette 3 months prior to first dose or cannot give up smoking during study； 6. The weekly alcohol consumption was higher than 14 units of alcohol (1 unit=10ml or 8g absolute alcohol. 25 ml 40% liquor, 330ml 5% beers, 175ml 12% grape wine are equal to 1.0, 1.5 and 2.0 units of alcohol respectively) 3 months prior to screening period, or positive test for the alcohol breath test results during screening period； 7. Those have history of drug abuse or taking soft drug (i.e., marihuana); or the results of urine test in drugs were positive; 8. Participated in other clinical trials within 3 months before screening; 9. Received any drug within 14 days before taking the investigational drug; 10. Received any drugs that inhibit or induce the CYP450 enzyme (i.e., inducers- barbiturates, tegretol, phenytoin, rifampicin, hexadecadrol, rifabutin, rifapentini; inhibitors- SSRI-antidepressant, cimetidine, diltiazem, macrolides, verapamil, imidazoles- antifungal drugs) 30 days prior to screening period； 11. History of syncope / needle syncope and intolerable intravenous indwelling needle; 12. Those who have undergone major surgery within the first 6 months of the screening period; 13. Those who have habitual constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease； 14. Hemorrhoids or perianal disease with regular/perianal bleeding; 15. Significant radiation exposure within one year prior to drug administration (more than one exposure from chest X-ray, CT scan, or barium meal examination and radiation-related occupations); 16. Those who cannot complete this study because of other reasons, or any factors judged by investigator that the participants cannot meet.